Blog
Blog
AI-driven Advancements in Life Sciences
The momentum behind AI-driven advancements in life sciences has never been stronger, and this trend was spotlighted in Everest Group’s new 2025 PEAK Matrix® report, “Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.” Trinity Life Sciences is honored to be recognized as a Leader in this comprehensive assessment, a distinction rooted…
Filter posts by:
Blog
Verily to Acquire SignalPath, Expanding the Company’s Clinical Research Capabilities
Verily recently announced its first major acquisition, a software platform known as SignalPath. SignalPath’s flagship software, TrialPath, digitizes and modulates individual protocols in a clinical trial, from budgeting to tracking point-of-care communication. The acquisition would fold SignalPath into Baseline, Verily’s clinical research...
Blog
What Market Access Opportunities Exist for Rare Disease Products in China? An Analysis of Rare Disease Product Inclusion in the 2020 NRDL
Executive Summary Trinity’s Take: Due to the rapidly evolving rare disease policy environment in China, manufacturers should prepare to take a flexible approach to their rare disease product market access strategy. This would include considering alternative funding opportunities outside of the...
Blog
What Market Access Opportunities Exist for Oncology Products in China? An Analysis of Oncology Product Inclusion in the 2020 NRDL
Executive Summary Trinity’s Take: While the NRDL presents increasing reimbursement opportunities for oncology products in China, pricing restrictions will remain as a key challenge. In order to defend pricing in NRDL negotiations, manufacturers should consider targeting indications with high unmet needs...
Blog
CMS Hospital Pricing Transparency: One Price Fits All?
Executive Summary: Trinity’s Take: Although the rule increases hospital pricing transparency and grants American patients a better estimate of their hospital’s costs prior to receiving care, low penalties, limited enforcement, and site of care loopholes lessen the impact of CMS’ Hospital...
Blog
Is the Pricing Discount for Chinese NRDL Inclusion Worth it? NRDL Commercial Impact Assessment
Executive Summary Trinity’s Take: Based on the short-term follow up sales data, the increase in average sales revenue and volume growth offset the average price discount for the majority of NRDL listed products in 2017, which justifies the steep price cut...
Blog
Poland’s Medical Fund Bill to Improve Access to Oncology Drugs
Executive Summary Trinity’s Take: The recently introduced Medical Fund Bill has potential to improve access to novel therapies applying for reimbursement in Poland, however, it is yet to be seen how the criteria for inclusion in the Fund’s list are clarified...
